新股消息 | 龙丰集团递表港交所 为香港最大的药品零售商

Company Overview - Long Fung Group Holdings Limited is a leading retail pharmacy operator based in Hong Kong, with a market share of 5.2% in retail sales of pharmaceuticals, making it the largest in the sector according to Frost & Sullivan [3] - The company operates 29 retail stores and various online sales platforms, offering a wide range of products across 11 categories, including traditional Chinese medicine, Western medicine, health supplements, skincare, cosmetics, and household goods [3][4] - The flagship store located in Mong Kok is the largest pharmacy retail store in Hong Kong by total floor area, measuring approximately 17,500 square feet [3] Product Offering - The company has sold over 46,000 product SKUs during the historical period, with an average of 8,000 SKUs stocked per store, and larger stores offering up to 13,000 SKUs [5][6] - The product range includes over 3,000 pharmaceutical items, more than 4,200 health products, over 6,800 beauty products, and over 14,000 other consumer products [5] Supplier Network - The company sources products from over 600 suppliers globally, including local distributors in Hong Kong and major suppliers from Japan, South Korea, Southeast Asia, Europe, and the United States [4] - It has established a supply chain office in Fukuoka, Japan, to procure local products that appeal to its target customers [4] Financial Performance - The company's revenue for the fiscal years 2023, 2024, 2025, and the first quarter of 2026 is approximately HKD 1.094 billion, HKD 2.021 billion, HKD 2.460 billion, and HKD 697 million respectively [7] - The profit figures for the same periods are approximately HKD -27.14 million, HKD 145.36 million, HKD 170.43 million, and HKD 47.76 million [8] - The gross profit margins for these fiscal years are 24.9%, 29.3%, 31.6%, and 31.9% respectively [9] Industry Overview - The total retail sales of consumer goods in Hong Kong are projected to grow from HKD 326.5 billion in 2020 to HKD 376.8 billion in 2024, with a compound annual growth rate (CAGR) of 3.6% [11] - The pharmaceutical market in Hong Kong is expected to grow from approximately HKD 5.8 billion in 2020 to HKD 8.5 billion in 2024, driven by an aging population and increased healthcare spending, with a CAGR of 10.1% [15]